Results 261 to 270 of about 1,721,954 (363)

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Precision Microbiome: A New Era of Targeted Therapy with Core Probiotics. [PDF]

Research (Wash D C)
Fang X, Wang Y, Wei H, Huang Y.
europepmc   +1 more source

Proteins of the sarcoplasmic reticulum as potential targets for gene therapy of heart failure [PDF]

, 2000
Jos M. J. Lamers, Karel Bezstarosti, Karin Eizema, Henry Fechner, Heinz‐Peter Schultheiss, Wolfgang Poller   +5 more
openalex   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

HPV-driven cancers: a looming threat and the potential of CRISPR/Cas9 for targeted therapy. [PDF]

Virol J
Kermanshahi AZ, Ebrahimi F, Taherpoor A, Eslami N, Baghi HB.   +4 more
europepmc   +1 more source

EFFICIENT GENE DELIVERY TO VASCULAR SMOOTH MUSCLE CELLS USING A NONTOXIC, SYNTHETIC PEPTIDE VECTOR SYSTEM TARGETED TO MEMBRANE INTEGRINS: A FIRST STEP TOWARD THE GENE THERAPY OF CHRONIC REJECTION1

, 2000
Jian‐Mei Li, Louise Collins, Xiaohong Zhang, Kenth Gustafsson, John W. Fabre   +4 more
openalex   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Next-Generation Sequencing in Oncology-A Guiding Compass for Targeted Therapy and Emerging Applications. [PDF]

Int J Mol Sci
Galeș LN, Păun MA, Butnariu I, Simion L, Manolescu LSC, Trifănescu OG, Anghel RM.   +6 more
europepmc   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

Peptide Aptamer-Paclitaxel Conjugates for Tumor Targeted Therapy. [PDF]

Pharmaceutics
Shen X, Ma Y, Luo H, Abdullah R, Pan Y, Zhang Y, Zhong C, Zhang B, Zhang G.   +8 more
europepmc   +1 more source